Inter-method variability in PTH measurement: implication for the care of CKD patients.
about
Estimation of the stability of parathyroid hormone when stored at -80 degrees C for a long period.Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.Intervariability among serum intact parathyroid hormone assays: a need for standardization.Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir usersDifferences between hospitals in attainment of parathyroid hormone treatment targets in chronic kidney disease do not reflect differences in quality of care.Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort studySerum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature reviewMineral metabolism in European children living with a renal transplant: a European society for paediatric nephrology/european renal association-European dialysis and transplant association registry studyThe five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patientsIntact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapySerum calcium and phosphorus levels in patients undergoing maintenance hemodialysis: A multicentre study in Korea.The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidismMineral metabolism disturbances in patients with chronic kidney disease.Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantationPrecision of biomarkers to define chronic inflammation in CKD.Association of serum intact parathyroid hormone with lower estimated glomerular filtration rateTiming of onset of CKD-related metabolic complicationsCalcium metabolism in the early posttransplantation period.Lessons from a second- and third-generation parathyroid hormone assays in renal failure patients.Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism.Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questionsInterpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory?Diseases of the parathyroid gland in chronic kidney disease.Parathyroid hormone measurement in chronic kidney disease--an evolving issue for the nephrologist and the clinical laboratorist: minireview.Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group.Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international cohort studies.Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.How the reference values for serum parathyroid hormone concentration are (or should be) established?Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients.Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activationVariation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease.Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.COSMOS: the dialysis scenario of CKD-MBD in Europe.Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism.Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients.Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH.
P2860
Q33560470-09B915E9-CA67-490B-A935-FA5C164D76FDQ33899996-29070878-34E8-4970-BBBF-5BE6C39758A9Q34083341-F98D6DEF-89CC-40B6-90A9-9E9D117D69F2Q34213832-071592DE-4EAF-4FD2-8E0B-36290A65B32EQ34367731-AF22133B-2EF1-4118-8093-6980F3C8487FQ34538433-D6D13798-3481-45CD-B847-A4B44292C045Q35023526-D8201484-770E-49FD-A23E-04F23902AF4AQ35573599-EFA432DF-FDA8-4607-B0B1-A676124B2B0BQ35576091-CE59B503-0B1D-493F-B1FB-B850692210BCQ35848015-61EC113D-E325-459D-A662-94C4D1F02398Q35977337-AC603A4A-1759-47AF-A2BD-85CE76899CA5Q36466029-E49753C1-6149-448F-9237-7CE52AC51ABAQ36666922-EB6FECB4-6CC0-41D7-BE49-EE9057F0FD3DQ36884206-FFB0DA64-9004-4DC9-B3AA-888E8CC2E4C2Q36947345-1BCA33FA-C747-4D91-AF22-A453D97C24D7Q36952786-59516479-0540-4BF5-8711-46D6845F3C93Q37042087-28B42746-1541-4114-9F74-C3E0E9183486Q37042178-C66DB5CC-6CF8-4D44-8D25-BC377101A959Q37123164-7F2C5D8E-121C-448B-8A96-81F82D06F828Q37193520-F2176579-9DAD-4A50-ACA3-622B37CD8176Q37193525-CC846CAF-8E40-458C-9D1C-F0435A196F30Q37228193-6964F091-31FC-4250-A0EA-3F9B86A5C84DQ37713739-6F502EC8-EADB-4B37-A221-0AEC3DF51282Q37912038-686D93DC-3BC2-4599-9333-B9EA9BC0BC79Q37972396-359BBEFD-DFD0-4723-91FC-70DEBB82CDBDQ38034435-6695423D-62B1-4628-934C-07E70FBE6043Q38034690-6BB564C8-8BE7-4B5B-97FA-4642335A2850Q38572880-3B28BA26-14BA-4DA4-A107-397FE28B376BQ38828618-8F22CC13-12C5-4407-8852-BFD583EB236AQ38970634-5FF04A54-2695-44CC-84FD-17A5CEA779FDQ39220825-023E4D8E-CE5B-48A0-BF26-845A84255867Q42282597-4BE46A09-C716-480C-9AEB-94FA3080F008Q42727533-CA879E44-39FF-43B9-BE66-8C73C5E129B9Q42951724-02E2925A-EC06-49D0-A359-E8EEA666D030Q43427754-350D20E7-FB40-46B7-92C2-3E6AB7FF77F2Q43826461-F7565381-73BD-4212-A024-BC151E777485Q43939289-F4975AE9-738C-4A77-86D7-E2E3AC22B2AAQ44227454-59329C85-7B23-44EC-A7CD-61B43F5EBB7CQ44410394-019E8E9F-1976-44B2-BD43-8C746C9E267CQ44434530-AFFEDCD4-D898-4201-BD9F-B23F290AE641
P2860
Inter-method variability in PTH measurement: implication for the care of CKD patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Inter-method variability in PTH measurement: implication for the care of CKD patients.
@en
Inter-method variability in PTH measurement: implication for the care of CKD patients.
@nl
type
label
Inter-method variability in PTH measurement: implication for the care of CKD patients.
@en
Inter-method variability in PTH measurement: implication for the care of CKD patients.
@nl
prefLabel
Inter-method variability in PTH measurement: implication for the care of CKD patients.
@en
Inter-method variability in PTH measurement: implication for the care of CKD patients.
@nl
P2093
P356
P1433
P1476
Inter-method variability in PTH measurement: implication for the care of CKD patients.
@en
P2093
D Chevenne
E Lawson-Body
E Plouvier
G Coumaros
J-C Souberbielle
M-C Carlier
P2888
P304
P356
10.1038/SJ.KI.5001606
P407
P577
2006-06-21T00:00:00Z